SCYNEXIS, Inc: Extension of ACD/Labs NMR Processing Tools has Increased Efficiency and Helped Accelerate Drug Discovery and Development.

SCYNEXIS, Inc: Extension of ACD/Labs NMR Processing Tools has Increased Efficiency and Helped Accelerate Drug Discovery and Development.

Toronto, Canada, and North Carolina, USA (April 19, 2006)—Advanced Chemistry Development, Inc., (ACD/Labs) today announced that SCYNEXIS, Inc., a chemistry-focused drug discovery and development company, have expanded their installation of ACD/1D NMR Processor, which eases the interpretation of NMR data through advanced multiplet analysis, verification, and quantitation techniques, at their research facility located in Research Triangle Park, North Carolina.  As a result, average NMR interpretation and dissemination times have been cut dramatically.  This in turn helps speed the drug discovery and development project timelines of their research partners, which is critical in the competitive CRO marketplace. 

ACD/1D NMR Processor supports all major NMR formats and brings an array of processing and analysis tools to the scientist’s desktop.  The software is designed to complement the chemist's interpretation workflow and speeds up the process of turning data into the information required to direct a medicinal chemistry program.  Tools like J-Coupler, the multiplet analysis tool, are used to efficiently gather spectral features, which accelerates the preparation of patents and allows chemists to focus on chemistry.

Dr. Darryl LeBlanc, Research Investigator, reflects, “When SCYNEXIS was formed in 2000, we initially had no NMR software other than at the workstations on the instruments.  SCYNEXIS management’s decision to provide desktop NMR processing and analysis tools for all our chemists in 2001 resulted in a huge boost in efficiency.”

SCYNEXIS scientists utilize ACD/Labs’ extensive databases containing chemical shift values from literature, along with spectral prediction software to facilitate the rapid identification of reaction products and impurities.  Routine NMR data processing tasks are automated via macros to improve speed and consistency in an open-access environment.  These gains are particularly noticeable for chemical libraries, in which NMR spectra for each member is processed identically in minutes.  The flexibility of report formatting in ACD/ChemSketch accommodates the reporting needs of the wide array of projects at SCYNEXIS.

Further information on how ACD/Labs’ software can be used to increase efficiency in open-access laboratories, may be found at http://www.acdlabs.com/openaccess/

About Advanced Chemistry Development

Advanced Chemistry Development, Inc., (ACD/Labs) is a chemistry software company offering solutions that truly integrate chemical structures with analytical chemistry information to produce ChemAnalytics^®.  ACD/Labs creates innovative software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, elucidation of unknown substances, chromatographic separation, medicinal chemistry, preformulation of novel drug agents, systematic nomenclature generation, and chemical patenting and publication.  Combined, ACD/Labs' solutions create an analytical informatics system that provides dramatic feed-forward effects on the chemical and pharmaceutical research process.  Founded in 1993, and headquartered in Toronto, Canada, ACD/Labs employs a team of over 100 dedicated individuals whose continual efforts carry ACD/Labs' innovative technologies into pharmaceutical, biotech, chemical, and materials companies throughout the world.  Information about Advanced Chemistry Development and its products can be found at www.acdlabs.com.

About SCYNEXIS

SCYNEXIS, Inc. is a chemistry-focused drug discovery and development company headquartered in Research Triangle Park, North Carolina. Its scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery of innovative medicines over a broad range of therapy areas.

In the discovery phase SCYNEXIS offers its services primarily in the form of integrated research teams consisting of medicinal chemists, computational chemists, analytical chemists and bioanalytical scientists to work on a collaborative basis with our customers on projects from hit to candidate selection.  SCYNEXIS project leaders of these multi-disciplinary teams are knowledgeable scientists with years of industry experience. They coordinate and communicate key activities and drive resources to achieve success.  SCYNEXIS research teams use powerful, proprietary technologies such as the HEOS® Software Suite, MEDCHEM-FACTORY™ and KIT™ Kinase Inhibitor Technology to deliver maximum results to our customers. Development phase services such as process chemistry, cGMP synthesis and bioanalytical are available on a fee for service project basis. SCYNEXIS has tailored our development teams to be especially effective in moving your project from discovery to the clinic. By linking good science with regulatory compliance, SCYNEXIS ensures projects are completed to meet both a

client’s expectations and current GMP/GLP guidelines. Please visit www.scynexis.com for more information.